Lantheus Holdings, Inc.

LNTHNasdaq· In Vitro & In Vivo Diagnostic Substances

Price History

Revenue

$1.5B

▲ 0.5% YoY

Net Income

$233.6M

▼ 25.2% YoY

EPS

$3.41

▼ 21.8% YoY

Cash

$359.1M

▼ 60.7% YoY

FY 2025 · As of 2025-12-31

Pro

10-K Year-over-Year Diff

AI-powered analysis of what changed between the last two annual reports — new risks, removed language, strategy shifts.